Review Papers Claim by Claim

Visual first — concise figures summarizing the review

Visual summary — what the paper claims (with direct primary-source anchors)

• IMP2 (IGF2BP2) is an m6A reader that stabilizes and/or enhances translation of m6A-modified RNAs; central citation used by the review: Huang et al. (IGF2BP m6A reader) IGF2BP m6A reader mechanism
• Review compiles tissue/cancer-specific targets (HK2, GLUT1, CDC45, MYC, PDX1, HK2 via CASC9, etc.) and links IMP2 to glycolysis/Warburg phenotype across multiple malignancies; core review source: Das et al. (2025) IMP2 Review (Das et al.)

Critical appraisal — strengths

1. Breadth and currency: synthesizes >150 references (mechanistic papers, preprints, 2023–2024 data) and integrates structure, biochemistry, in vivo models, and clinical datasets IMP2 Review breadth.
2. Mechanistic grounding: references primary biochemical/structural investigations of IMP2 dimerization and RNA-induced conformational changes (structural preprint doi:10.1101/2024.02.16.580656) used to justify molecular models mentioned in the review IMP2 structural preprint.

Critical appraisal — limitations, biases, blindspots

• Narrative (non-systematic) review design: selection bias likely (authors did not describe systematic search/PRISMA-like flow), so some negative/contradictory studies may be under-weighted — reduces reproducibility and impartiality of conclusions Narrative-review limitation.
• Over-generalization across tissues: many mechanistic conclusions come from specific cell lines or mice and are extrapolated pan-cancer; but the review itself acknowledges context-dependence (e.g., IMP2 can suppress metastasis in ccRCC) — this heterogeneity needs clearer emphasis and more critical weighting of evidence by model type Context-dependence noted.
• Database analyses are presented but methods are thin: GEPIA2/cBioPortal/Kaplan‑Meier analyses appear in figures and text but the review lacks reproducible code, thresholds, sample counts per comparison, or multiple-testing corrections — reduces reproducibility of those claims Public-database analyses without methods.
• Therapeutic claims are premature: small-molecule IMP2 inhibitors exist (Dahlem et al., ACS Chem Biol 2022) but off-targets and modest rescue in knockout cells were reported; the review mentions inhibitors but should weigh pharmacology limitations more heavily IMP2 inhibitors (Dahlem et al.).

Where the review is persuasive vs where more evidence is needed

• Persuasive: biochemical role as an m6A reader (strong primary evidence) and repeated independent reports of IMP2 stabilizing glycolytic mRNAs (HK2, GLUT1) across cancer models — multiple papers converge on this axis IGF2BP m6A reader mechanism m6A–glycolysis link
• Needs stronger evidence: causality linking human IGF2BP2 SNPs (rs4402960/rs1470579) to T2D — GWAS association is reproducible in many cohorts but effect sizes are small and not mechanistically proven in humans; review cites meta-analyses but could emphasize heterogeneity across populations IGF2BP2 GWAS link to T2D.

Practical reproducibility checklist (what I would need to reproduce/extend the review analyses)

1. Exact GEPIA2/cBioPortal/Kaplan‑Meier queries (dataset versions, tumor types, normalization/TPM thresholds, logFC cutoffs, multiple-testing corrections).
2. List of CLIP/MeRIP/RIP datasets used (accession IDs) and the POSTAR3 queries/filters employed.
3. Code / notebooks used to generate figures (ideally deposited in GitHub or as supporting scripts).
4. Detailed description of how therapeutic inhibitor screens were filtered and validated (off-target controls, orthogonal assays).

Concrete, practical recommendations to improve the paper (and next experiments)

• Provide a transparent methods supplement describing exact database queries and analysis scripts (reproducible code + parameters).
• Include a table that grades each reported IMP2 target by level of evidence (CLIP vs MeRIP vs functional rescue vs in vivo phenotype).
• When discussing inhibitors, add detailed chemotype validation: orthogonal binding assays, CETSA/thermal shift in purified systems and cells, and target engagement in vivo.
• Quantitatively separate evidence from cell lines, mouse models, and human clinical data throughout the text and figures.

Key short conclusions and confidence

Top-line: IMP2/IGF2BP2 is a validated m6A reader with repeated functional evidence for stabilizing/boosting translation of metabolic and oncogenic RNAs; the review is valuable as a synthesis and resource, but because it is narrative and mixes heterogeneous evidence without full methods reproducibility, some translational and prognostic claims should be treated as hypothesis-generating rather than definitive. Confidence: 7/10 for the paper's central mechanistic claims, 5–6/10 for pan-cancer prognostic/therapeutic conclusions pending reproducible data and orthogonal validation IMP2 Review limitations noted.

Author review links

Next actions (if you want me to continue)

I can:
- Re-run the GEPIA2 / cBioPortal / Kaplan‑Meier queries and produce reproducible figures and code
- Build an evidence table grading each IMP2 target with accessioned CLIP/MeRIP datasets and functional validation levels
- Cross-validate reported small-molecule inhibitors against chemoproteomics data and off-target predictions

Primary citations used in this critique: the review itself (Das et al., DOI 10.3390/ijms26062415) and the foundational IGF2BP m6A reader paper (Huang et al., Nat Cell Biol 2018 DOI 10.1038/s41556-018-0045-z); additional methodological/therapeutic context cited inline within the critique (structural preprint and small-molecule inhibitor report).